Details of the Drug Combinations

General Information of This Drug (ID: DMFGYKS)

Drug Name
MK-5108   DMFGYKS
Synonyms
1010085-13-8; VX-689; MK 5108; MK5108; MK-5108 (VX-689); UNII-H8J407531S; VX689; VX 689; CHEMBL3600873; H8J407531S; 4-(3-chloro-2-fluorophenoxy)-1-[[6-(1,3-thiazol-2-ylamino)pyridin-2-yl]methyl]cyclohexane-1-carboxylic acid; 4-(3-Chloranyl-2-Fluoranyl-Phenoxy)-1-[[6-(1,3-Thiazol-2-Ylamino)pyridin-2-Yl]methyl]cyclohexane-1-Carboxylic Acid; (1r,4r)-4-(3-chloro-2-fluorophenoxy)-1-((6-(thiazol-2-ylamino)pyridin-2-yl)methyl)cyclohexane-1-carboxylic acid; Cyclohexanecarboxylic acid,; MK-5108/VX-689
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

568 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Cyclophosphamide + MK-5108 DCQVX3U Cyclophosphamide Malignant melanoma (Cell Line: A375) [2]
Cyclophosphamide + MK-5108 DCO7ST1 Cyclophosphamide Malignant melanoma (Cell Line: HT144) [2]
Cyclophosphamide + MK-5108 DCLZQHY Cyclophosphamide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Cyclophosphamide + MK-5108 DC5UPE0 Cyclophosphamide Colon carcinoma (Cell Line: RKO) [3]
Cyclophosphamide + MK-5108 DCC43RE Cyclophosphamide Rectal adenocarcinoma (Cell Line: SW837) [3]
Dexamethasone + MK-5108 DC0M25W Dexamethasone Breast carcinoma (Cell Line: KPL1) [3]
Dexamethasone + MK-5108 DCZLEFX Dexamethasone Colon carcinoma (Cell Line: RKO) [3]
Dexamethasone + MK-5108 DCDXH5S Dexamethasone Rectal adenocarcinoma (Cell Line: SW837) [3]
Dexamethasone + MK-5108 DCLOB6S Dexamethasone Adenocarcinoma (Cell Line: CAOV3) [4]
Dexamethasone + MK-5108 DC6E1IO Dexamethasone Adenocarcinoma (Cell Line: DLD1) [4]
Dexamethasone + MK-5108 DC1WR3D Dexamethasone Adenocarcinoma (Cell Line: HT29) [4]
Dexamethasone + MK-5108 DC1I7LO Dexamethasone Malignant melanoma (Cell Line: A375) [4]
Dexamethasone + MK-5108 DCXVVRM Dexamethasone Malignant melanoma (Cell Line: HT144) [4]
Dexamethasone + MK-5108 DC2MSQ5 Dexamethasone Malignant melanoma (Cell Line: SKMEL30) [4]
Dexamethasone + MK-5108 DCXCT6J Dexamethasone Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Doxorubicin + MK-5108 DCLQEJA Doxorubicin Adenocarcinoma (Cell Line: NCIH23) [2]
Doxorubicin + MK-5108 DCM5SSN Doxorubicin Adenocarcinoma (Cell Line: DLD1) [2]
Doxorubicin + MK-5108 DC5YECW Doxorubicin Malignant melanoma (Cell Line: RPMI7951) [2]
Doxorubicin + MK-5108 DCTWMU4 Doxorubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
Estramustine + MK-5108 DCTUOIW Estramustine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
Estramustine + MK-5108 DCK59SF Estramustine Breast carcinoma (Cell Line: OCUBM) [3]
Estramustine + MK-5108 DC94B58 Estramustine Carcinoma (Cell Line: EFM192B) [3]
Estramustine + MK-5108 DC77C9F Estramustine Colon carcinoma (Cell Line: RKO) [3]
Estramustine + MK-5108 DCROSU1 Estramustine Adenocarcinoma (Cell Line: CAOV3) [4]
Estramustine + MK-5108 DCFLH11 Estramustine Adenocarcinoma (Cell Line: NCIH23) [4]
Estramustine + MK-5108 DCR2FV7 Estramustine Adenocarcinoma (Cell Line: COLO320DM) [4]
Estramustine + MK-5108 DC1VTGF Estramustine Adenocarcinoma (Cell Line: DLD1) [4]
Estramustine + MK-5108 DC2NERJ Estramustine Adenocarcinoma (Cell Line: HT29) [4]
Estramustine + MK-5108 DCJ70UI Estramustine Amelanotic melanoma (Cell Line: A2058) [4]
Estramustine + MK-5108 DCZTFSZ Estramustine Germ cell tumour (Cell Line: PA1) [4]
Estramustine + MK-5108 DCGMPWJ Estramustine Malignant melanoma (Cell Line: A375) [4]
Estramustine + MK-5108 DCD30UN Estramustine Malignant melanoma (Cell Line: RPMI7951) [4]
Estramustine + MK-5108 DCRJN2P Estramustine Malignant melanoma (Cell Line: SKMEL30) [4]
Estramustine + MK-5108 DC6RPZ8 Estramustine Malignant melanoma (Cell Line: UACC62) [4]
Estramustine + MK-5108 DCZU85E Estramustine Mesothelioma (Cell Line: MSTO) [4]
Estramustine + MK-5108 DCYIFMU Estramustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Estramustine + MK-5108 DCBIT89 Estramustine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Etoposide + MK-5108 DCYI0SI Etoposide Adenocarcinoma (Cell Line: CAOV3) [2]
Etoposide + MK-5108 DC73F9R Etoposide Adenocarcinoma (Cell Line: A427) [2]
Etoposide + MK-5108 DCICOME Etoposide Adenocarcinoma (Cell Line: NCIH23) [2]
Etoposide + MK-5108 DCDLKIR Etoposide Adenocarcinoma (Cell Line: DLD1) [2]
Etoposide + MK-5108 DCBWLK5 Etoposide Adenocarcinoma (Cell Line: HCT116) [2]
Etoposide + MK-5108 DCO31Q7 Etoposide Adenocarcinoma (Cell Line: HT29) [2]
Etoposide + MK-5108 DCBDCE7 Etoposide Adenocarcinoma (Cell Line: SW-620) [2]
Etoposide + MK-5108 DC8PBXB Etoposide Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
Etoposide + MK-5108 DCGFQOX Etoposide Germ cell tumour (Cell Line: PA1) [2]
Etoposide + MK-5108 DCKOU9F Etoposide Malignant melanoma (Cell Line: RPMI7951) [2]
Etoposide + MK-5108 DCSPQFF Etoposide Malignant melanoma (Cell Line: SKMEL30) [2]
Etoposide + MK-5108 DCFSVO3 Etoposide Malignant melanoma (Cell Line: UACC62) [2]
Etoposide + MK-5108 DCYVDYU Etoposide Mesothelioma (Cell Line: MSTO) [2]
Etoposide + MK-5108 DCARDKE Etoposide Non small cell carcinoma (Cell Line: SKMES1) [2]
Etoposide + MK-5108 DCNKB04 Etoposide Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
Etoposide + MK-5108 DC1R8Q3 Etoposide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Etoposide + MK-5108 DC49G70 Etoposide Breast carcinoma (Cell Line: OCUBM) [3]
Etoposide + MK-5108 DCSP5GN Etoposide Carcinoma (Cell Line: OV90) [3]
Etoposide + MK-5108 DCIYN3G Etoposide Carcinoma (Cell Line: EFM192B) [3]
Etoposide + MK-5108 DCOMNYX Etoposide Carcinoma (Cell Line: MDAMB436) [3]
Etoposide + MK-5108 DCY4I5V Etoposide Colon carcinoma (Cell Line: RKO) [3]
Fluorouracil + MK-5108 DCO3423 Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Fluorouracil + MK-5108 DCYS5SM Fluorouracil Breast carcinoma (Cell Line: KPL1) [3]
Fluorouracil + MK-5108 DC37RHA Fluorouracil Breast carcinoma (Cell Line: OCUBM) [3]
Fluorouracil + MK-5108 DC75LWR Fluorouracil Colon carcinoma (Cell Line: RKO) [3]
Fluorouracil + MK-5108 DCCWWH1 Fluorouracil Rectal adenocarcinoma (Cell Line: SW837) [3]
Fluorouracil + MK-5108 DCBAMAA Fluorouracil Adenocarcinoma (Cell Line: CAOV3) [4]
Fluorouracil + MK-5108 DCUJCNR Fluorouracil Adenocarcinoma (Cell Line: A427) [4]
Fluorouracil + MK-5108 DC4U7JQ Fluorouracil Adenocarcinoma (Cell Line: NCIH1650) [4]
Fluorouracil + MK-5108 DC41DNU Fluorouracil Adenocarcinoma (Cell Line: NCIH23) [4]
Fluorouracil + MK-5108 DCJDN30 Fluorouracil Adenocarcinoma (Cell Line: COLO320DM) [4]
Fluorouracil + MK-5108 DCSVXSP Fluorouracil Adenocarcinoma (Cell Line: HCT116) [4]
Fluorouracil + MK-5108 DC8Q4TK Fluorouracil Adenocarcinoma (Cell Line: HT29) [4]
Fluorouracil + MK-5108 DC7B8OW Fluorouracil Germ cell tumour (Cell Line: PA1) [4]
Fluorouracil + MK-5108 DCNZ1FN Fluorouracil Malignant melanoma (Cell Line: A375) [4]
Fluorouracil + MK-5108 DCL9MMF Fluorouracil Malignant melanoma (Cell Line: RPMI7951) [4]
Fluorouracil + MK-5108 DCJ0W1R Fluorouracil Malignant melanoma (Cell Line: SKMEL30) [4]
Fluorouracil + MK-5108 DC868I4 Fluorouracil Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Fluorouracil + MK-5108 DCJL3S3 Fluorouracil Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Gemcitabine + MK-5108 DCWDZPD Gemcitabine Adenocarcinoma (Cell Line: CAOV3) [2]
Gemcitabine + MK-5108 DCKORVQ Gemcitabine Adenocarcinoma (Cell Line: NCIH520) [2]
Gemcitabine + MK-5108 DC5CQA5 Gemcitabine Adenocarcinoma (Cell Line: DLD1) [2]
Gemcitabine + MK-5108 DCC6CDR Gemcitabine Amelanotic melanoma (Cell Line: A2058) [2]
Gemcitabine + MK-5108 DC2N4XJ Gemcitabine Malignant melanoma (Cell Line: HT144) [2]
Gemcitabine + MK-5108 DCYK8UU Gemcitabine Non small cell carcinoma (Cell Line: SKMES1) [2]
Gemcitabine + MK-5108 DCEYB2J Gemcitabine Carcinoma (Cell Line: EFM192B) [3]
Gemcitabine + MK-5108 DCOI063 Gemcitabine Invasive ductal carcinoma (Cell Line: T-47D) [3]
Idarubicin + MK-5108 DC5COV0 Idarubicin Colon carcinoma (Cell Line: RKO) [3]
Idarubicin + MK-5108 DC46JGB Idarubicin Rectal adenocarcinoma (Cell Line: SW837) [3]
Idarubicin + MK-5108 DCFX184 Idarubicin Adenocarcinoma (Cell Line: A427) [4]
Idarubicin + MK-5108 DC70V0L Idarubicin Adenocarcinoma (Cell Line: NCIH23) [4]
Idarubicin + MK-5108 DC5J8GB Idarubicin Malignant melanoma (Cell Line: RPMI7951) [4]
Idarubicin + MK-5108 DC5IEVE Idarubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Idarubicin + MK-5108 DCNGA17 Idarubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Lapatinib + MK-5108 DCWIP4F Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Lapatinib + MK-5108 DC857MR Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Lapatinib + MK-5108 DCJ3GIX Lapatinib Breast carcinoma (Cell Line: OCUBM) [3]
Lapatinib + MK-5108 DCDUNLJ Lapatinib Carcinoma (Cell Line: EFM192B) [3]
Lapatinib + MK-5108 DCM8K8T Lapatinib Colon adenocarcinoma (Cell Line: LOVO) [3]
Lapatinib + MK-5108 DCVCROF Lapatinib Colon carcinoma (Cell Line: RKO) [3]
Lapatinib + MK-5108 DCGBWQ7 Lapatinib Adenocarcinoma (Cell Line: CAOV3) [4]
Lapatinib + MK-5108 DCBUJM5 Lapatinib Adenocarcinoma (Cell Line: OVCAR3) [4]
Lapatinib + MK-5108 DC5JDCW Lapatinib Adenocarcinoma (Cell Line: A427) [4]
Lapatinib + MK-5108 DC74E5U Lapatinib Adenocarcinoma (Cell Line: NCIH1650) [4]
Lapatinib + MK-5108 DCCA7UO Lapatinib Adenocarcinoma (Cell Line: NCIH23) [4]
Lapatinib + MK-5108 DC6IYBF Lapatinib Adenocarcinoma (Cell Line: COLO320DM) [4]
Lapatinib + MK-5108 DC1YJUD Lapatinib Adenocarcinoma (Cell Line: DLD1) [4]
Lapatinib + MK-5108 DCLZLZF Lapatinib Adenocarcinoma (Cell Line: HCT116) [4]
Lapatinib + MK-5108 DCD36I8 Lapatinib Adenocarcinoma (Cell Line: HT29) [4]
Lapatinib + MK-5108 DC3JF88 Lapatinib Amelanotic melanoma (Cell Line: A2058) [4]
Lapatinib + MK-5108 DC346TM Lapatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Lapatinib + MK-5108 DC6HQTJ Lapatinib Malignant melanoma (Cell Line: A375) [4]
Lapatinib + MK-5108 DCXLBD2 Lapatinib Malignant melanoma (Cell Line: HT144) [4]
Lapatinib + MK-5108 DCIZ5SN Lapatinib Malignant melanoma (Cell Line: RPMI7951) [4]
Lapatinib + MK-5108 DC2LUNB Lapatinib Malignant melanoma (Cell Line: SKMEL30) [4]
Lapatinib + MK-5108 DCF8N2D Lapatinib Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + MK-5108 DC56TEL Lapatinib Mesothelioma (Cell Line: MSTO) [4]
Lapatinib + MK-5108 DCZ4ZT5 Lapatinib Non small cell carcinoma (Cell Line: SKMES1) [4]
Lapatinib + MK-5108 DCDIUAT Lapatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + MK-5108 DCYFM9K Lapatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Lapatinib + MK-5108 DCC9HJ7 Lapatinib Prostate carcinoma (Cell Line: VCAP) [4]
Metformin + MK-5108 DCGTMIK Metformin Adenocarcinoma (Cell Line: NCIH520) [2]
Metformin + MK-5108 DCW7HH5 Metformin Adenocarcinoma (Cell Line: HT29) [2]
Metformin + MK-5108 DC0BD5V Metformin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
Metformin + MK-5108 DCU9YJG Metformin Malignant melanoma (Cell Line: A375) [2]
Metformin + MK-5108 DCGBX6L Metformin Malignant melanoma (Cell Line: RPMI7951) [2]
Metformin + MK-5108 DC57WKU Metformin Malignant melanoma (Cell Line: UACC62) [2]
Metformin + MK-5108 DC1OVJ5 Metformin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Metformin + MK-5108 DC4U3XU Metformin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Metformin + MK-5108 DC4NZTV Metformin Breast carcinoma (Cell Line: OCUBM) [3]
Metformin + MK-5108 DCTDOCN Metformin Colon carcinoma (Cell Line: RKO) [3]
Methotrexate + MK-5108 DCE4CEO Methotrexate Adenocarcinoma (Cell Line: NCIH23) [2]
Methotrexate + MK-5108 DCO8U4X Methotrexate Adenocarcinoma (Cell Line: COLO320DM) [2]
Methotrexate + MK-5108 DCD0OMB Methotrexate Malignant melanoma (Cell Line: RPMI7951) [2]
Methotrexate + MK-5108 DCPRYQC Methotrexate Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
Methotrexate + MK-5108 DCIP3AB Methotrexate Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Mitomycin + MK-5108 DCDTMU8 Mitomycin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
Mitomycin + MK-5108 DCW5EAA Mitomycin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Mitomycin + MK-5108 DCUK3G5 Mitomycin Colon adenocarcinoma (Cell Line: LOVO) [3]
Mitomycin + MK-5108 DCQ6MIY Mitomycin Adenocarcinoma (Cell Line: CAOV3) [4]
Mitomycin + MK-5108 DCS2JLQ Mitomycin Adenocarcinoma (Cell Line: A427) [4]
Mitomycin + MK-5108 DCBDO84 Mitomycin Adenocarcinoma (Cell Line: NCIH2122) [4]
Mitomycin + MK-5108 DCBGT33 Mitomycin Adenocarcinoma (Cell Line: NCIH23) [4]
Mitomycin + MK-5108 DCMWDYE Mitomycin Amelanotic melanoma (Cell Line: A2058) [4]
Mitomycin + MK-5108 DCIFDF1 Mitomycin Germ cell tumour (Cell Line: PA1) [4]
Mitomycin + MK-5108 DCVIHQZ Mitomycin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-5108 + PD-0325901 DC0Q87X PD-0325901 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
MK-5108 + MK-1775 DCDQSUA MK-1775 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
MK-5108 + RTB101 DCTOAFZ RTB101 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
MK-5108 + 10-hydroxycamptothecin DCX3LUQ 10-hydroxycamptothecin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
MK-5108 + SNX-2112 DCW3GE1 SNX-2112 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
MK-5108 + Zoledronate DCXFU95 Zoledronate Ewing sarcoma (Cell Line: TC-71) [2]
MK-5108 + Zoledronate DCJ6CUY Zoledronate Ewing sarcoma (Cell Line: EW-8) [2]
MK-5108 + Idarubicin DCZAIVY Idarubicin Glioblastoma? (Cell Line: T98G) [2]
MK-5108 + Bortezomib DCNFA39 Bortezomib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
MK-5108 + Sorafenib DCG8VQ0 Sorafenib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
MK-5108 + Vorinostat DCR7ZQO Vorinostat Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
MK-5108 + PD-0325901 DC80NPC PD-0325901 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
MK-5108 + PD-0325901 DCGXIRR PD-0325901 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
MK-5108 + PD-0325901 DC7P8L1 PD-0325901 Breast carcinoma (Cell Line: KPL1) [3]
MK-5108 + PD-0325901 DCME9QY PD-0325901 Breast carcinoma (Cell Line: OCUBM) [3]
MK-5108 + PD-0325901 DC08PA0 PD-0325901 Invasive ductal carcinoma (Cell Line: T-47D) [3]
MK-5108 + MK-1775 DCRX11K MK-1775 Breast carcinoma (Cell Line: OCUBM) [3]
MK-5108 + MK-1775 DC56HD2 MK-1775 Carcinoma (Cell Line: MDAMB436) [3]
MK-5108 + MK-1775 DCABBSQ MK-1775 Colon carcinoma (Cell Line: RKO) [3]
MK-5108 + MK-1775 DCYYN7D MK-1775 Invasive ductal carcinoma (Cell Line: T-47D) [3]
MK-5108 + MK-1775 DCUSAYP MK-1775 Rectal adenocarcinoma (Cell Line: SW837) [3]
MK-5108 + RTB101 DCPWM10 RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
MK-5108 + RTB101 DCI8VGW RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
MK-5108 + RTB101 DCJ0R7O RTB101 Breast carcinoma (Cell Line: OCUBM) [3]
MK-5108 + RTB101 DC0MBUE RTB101 Carcinoma (Cell Line: EFM192B) [3]
MK-5108 + RTB101 DCJSAE3 RTB101 Carcinoma (Cell Line: MDAMB436) [3]
MK-5108 + RTB101 DCG5Z5Q RTB101 Colon adenocarcinoma (Cell Line: LOVO) [3]
MK-5108 + RTB101 DCPB7L4 RTB101 Invasive ductal carcinoma (Cell Line: T-47D) [3]
MK-5108 + SCH-900776 DC2MX6C SCH-900776 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
MK-5108 + SCH-900776 DCWYU7K SCH-900776 Carcinoma (Cell Line: EFM192B) [3]
MK-5108 + 10-hydroxycamptothecin DCGRFMF 10-hydroxycamptothecin Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
MK-5108 + 10-hydroxycamptothecin DCK8NJU 10-hydroxycamptothecin Carcinoma (Cell Line: MDAMB436) [3]
MK-5108 + SNX-2112 DC4KNFP SNX-2112 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
MK-5108 + SNX-2112 DCQI2O1 SNX-2112 Breast carcinoma (Cell Line: OCUBM) [3]
MK-5108 + SNX-2112 DCEW1R4 SNX-2112 Carcinoma (Cell Line: EFM192B) [3]
MK-5108 + SNX-2112 DCIZUBV SNX-2112 Carcinoma (Cell Line: MDAMB436) [3]
MK-5108 + SNX-2112 DC4DE8O SNX-2112 Colon adenocarcinoma (Cell Line: LOVO) [3]
MK-5108 + SNX-2112 DCC6SSF SNX-2112 Invasive ductal carcinoma (Cell Line: T-47D) [3]
MK-5108 + Erlotinib DCOBHS3 Erlotinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
MK-5108 + Erlotinib DCS8BJ2 Erlotinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
MK-5108 + Erlotinib DCFUGT7 Erlotinib Breast carcinoma (Cell Line: KPL1) [3]
MK-5108 + Erlotinib DCIC8RS Erlotinib Breast carcinoma (Cell Line: OCUBM) [3]
MK-5108 + Erlotinib DCDD06T Erlotinib Carcinoma (Cell Line: EFM192B) [3]
MK-5108 + Erlotinib DCN4N4F Erlotinib Colon adenocarcinoma (Cell Line: LOVO) [3]
MK-5108 + Erlotinib DC3MKVG Erlotinib Colon carcinoma (Cell Line: RKO) [3]
MK-5108 + Erlotinib DCTE8LK Erlotinib Invasive ductal carcinoma (Cell Line: T-47D) [3]
MK-5108 + Erlotinib DCI88SZ Erlotinib Rectal adenocarcinoma (Cell Line: SW837) [3]
MK-5108 + Ridaforolimus DCC9PAX Ridaforolimus Colon adenocarcinoma (Cell Line: LOVO) [3]
MK-5108 + MK-4827 DCBGGSO MK-4827 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
MK-5108 + MK-4827 DC22EC6 MK-4827 Breast carcinoma (Cell Line: KPL1) [3]
MK-5108 + MK-4827 DCOJGWP MK-4827 Breast carcinoma (Cell Line: OCUBM) [3]
MK-5108 + MK-4827 DCSQ5YL MK-4827 Carcinoma (Cell Line: EFM192B) [3]
MK-5108 + MK-4827 DCLKJ8Q MK-4827 Colon carcinoma (Cell Line: RKO) [3]
MK-5108 + MK-4827 DCDIC8Q MK-4827 Invasive ductal carcinoma (Cell Line: T-47D) [3]
MK-5108 + MK-4827 DC30C6P MK-4827 Rectal adenocarcinoma (Cell Line: SW837) [3]
MK-5108 + Lomustine DCD6M7Z Lomustine Breast carcinoma (Cell Line: OCUBM) [3]
MK-5108 + Lomustine DC1J1GH Lomustine Colon carcinoma (Cell Line: RKO) [3]
MK-5108 + Bortezomib DC382MM Bortezomib Colon carcinoma (Cell Line: RKO) [3]
MK-5108 + GSK525762 DC7G1UH GSK525762 Carcinoma (Cell Line: MDAMB436) [3]
MK-5108 + GSK525762 DCQVTVP GSK525762 Colon carcinoma (Cell Line: RKO) [3]
MK-5108 + Sorafenib DC2V9N0 Sorafenib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
MK-5108 + Sorafenib DC14Q4A Sorafenib Breast carcinoma (Cell Line: ZR751) [3]
MK-5108 + Sorafenib DCQDCIA Sorafenib Breast carcinoma (Cell Line: KPL1) [3]
MK-5108 + Sorafenib DCLJRRL Sorafenib Breast carcinoma (Cell Line: OCUBM) [3]
MK-5108 + Sorafenib DC3WW2U Sorafenib Carcinoma (Cell Line: OV90) [3]
MK-5108 + Sorafenib DCATF7I Sorafenib Carcinoma (Cell Line: EFM192B) [3]
MK-5108 + Sorafenib DCQAJFU Sorafenib Colon carcinoma (Cell Line: RKO) [3]
MK-5108 + Sorafenib DCA7EXK Sorafenib Invasive ductal carcinoma (Cell Line: T-47D) [3]
MK-5108 + MK-2206 DCEMWQ4 MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
MK-5108 + MK-2206 DC25KX3 MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
MK-5108 + MK-2206 DCPAM01 MK-2206 Breast carcinoma (Cell Line: ZR751) [3]
MK-5108 + MK-2206 DCF9TP5 MK-2206 Breast carcinoma (Cell Line: KPL1) [3]
MK-5108 + MK-2206 DCH619Q MK-2206 Breast carcinoma (Cell Line: OCUBM) [3]
MK-5108 + Vorinostat DC1G6XU Vorinostat Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
MK-5108 + Vorinostat DCGZH4N Vorinostat Carcinoma (Cell Line: EFM192B) [3]
MK-5108 + Vorinostat DCEY35Z Vorinostat Carcinoma (Cell Line: MDAMB436) [3]
MK-5108 + Vorinostat DC4Z7Z3 Vorinostat Colon adenocarcinoma (Cell Line: LOVO) [3]
MK-5108 + Vorinostat DCDZDKF Vorinostat Invasive ductal carcinoma (Cell Line: T-47D) [3]
MK-5108 + Dasatinib DCLNW2S Dasatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
MK-5108 + Dasatinib DC8VII9 Dasatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
MK-5108 + Dasatinib DCS08RY Dasatinib Breast carcinoma (Cell Line: OCUBM) [3]
MK-5108 + Dasatinib DCIEB0V Dasatinib Carcinoma (Cell Line: MDAMB436) [3]
MK-5108 + Dasatinib DCVDAU3 Dasatinib Colon adenocarcinoma (Cell Line: LOVO) [3]
MK-5108 + Dasatinib DCUVADY Dasatinib Colon carcinoma (Cell Line: RKO) [3]
MK-5108 + PD-0325901 DCUM7NG PD-0325901 Adenocarcinoma (Cell Line: CAOV3) [4]
MK-5108 + PD-0325901 DCP5FA4 PD-0325901 Adenocarcinoma (Cell Line: NCIH23) [4]
MK-5108 + PD-0325901 DCR2KEB PD-0325901 Adenocarcinoma (Cell Line: DLD1) [4]
MK-5108 + PD-0325901 DCZ9FXX PD-0325901 Amelanotic melanoma (Cell Line: A2058) [4]
MK-5108 + PD-0325901 DCTCC4X PD-0325901 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
MK-5108 + PD-0325901 DCVMAWB PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-5108 + PD-0325901 DCL07DN PD-0325901 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
MK-5108 + MK-1775 DCOXEVO MK-1775 Adenocarcinoma (Cell Line: CAOV3) [4]
MK-5108 + MK-1775 DC44MSQ MK-1775 Adenocarcinoma (Cell Line: OVCAR3) [4]
MK-5108 + MK-1775 DCSO3XW MK-1775 Adenocarcinoma (Cell Line: A427) [4]
MK-5108 + MK-1775 DCC7BQ6 MK-1775 Adenocarcinoma (Cell Line: NCIH2122) [4]
MK-5108 + MK-1775 DCN623R MK-1775 Adenocarcinoma (Cell Line: NCIH23) [4]
MK-5108 + MK-1775 DCGQ7NR MK-1775 Adenocarcinoma (Cell Line: COLO320DM) [4]
MK-5108 + MK-1775 DC2M4QD MK-1775 Adenocarcinoma (Cell Line: HCT116) [4]
MK-5108 + MK-1775 DCUWAYC MK-1775 Adenocarcinoma (Cell Line: HT29) [4]
MK-5108 + MK-1775 DCBPBOT MK-1775 Adenocarcinoma (Cell Line: SW-620) [4]
MK-5108 + MK-1775 DCFA5RP MK-1775 Amelanotic melanoma (Cell Line: A2058) [4]
MK-5108 + MK-1775 DCIUM2S MK-1775 Germ cell tumour (Cell Line: PA1) [4]
MK-5108 + MK-1775 DCFSZYW MK-1775 Malignant melanoma (Cell Line: A375) [4]
MK-5108 + MK-1775 DCE0O1S MK-1775 Malignant melanoma (Cell Line: RPMI7951) [4]
MK-5108 + MK-1775 DCH60AA MK-1775 Malignant melanoma (Cell Line: SKMEL30) [4]
MK-5108 + MK-1775 DC45SSS MK-1775 Malignant melanoma (Cell Line: UACC62) [4]
MK-5108 + MK-1775 DCBDDWF MK-1775 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-5108 + MK-1775 DC7SDXK MK-1775 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
MK-5108 + MK-1775 DC3W8HM MK-1775 Prostate carcinoma (Cell Line: VCAP) [4]
MK-5108 + RTB101 DCGX3N2 RTB101 Adenocarcinoma (Cell Line: CAOV3) [4]
MK-5108 + RTB101 DC38E6Y RTB101 Adenocarcinoma (Cell Line: A427) [4]
MK-5108 + RTB101 DC3ZAIZ RTB101 Adenocarcinoma (Cell Line: NCIH2122) [4]
MK-5108 + RTB101 DCWSQJO RTB101 Adenocarcinoma (Cell Line: NCIH520) [4]
MK-5108 + RTB101 DCFXDSX RTB101 Adenocarcinoma (Cell Line: HT29) [4]
MK-5108 + RTB101 DC2YLWS RTB101 Amelanotic melanoma (Cell Line: A2058) [4]
MK-5108 + RTB101 DC6RGCD RTB101 Germ cell tumour (Cell Line: PA1) [4]
MK-5108 + RTB101 DCNKF7S RTB101 Malignant melanoma (Cell Line: HT144) [4]
MK-5108 + RTB101 DCJT0W2 RTB101 Malignant melanoma (Cell Line: RPMI7951) [4]
MK-5108 + RTB101 DCHAO2N RTB101 Malignant melanoma (Cell Line: SKMEL30) [4]
MK-5108 + RTB101 DCD44TR RTB101 Malignant melanoma (Cell Line: UACC62) [4]
MK-5108 + RTB101 DCSM853 RTB101 Mesothelioma (Cell Line: MSTO) [4]
MK-5108 + RTB101 DCZEFPF RTB101 Non small cell carcinoma (Cell Line: SKMES1) [4]
MK-5108 + RTB101 DCHAJJC RTB101 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-5108 + RTB101 DC9I9LM RTB101 Prostate carcinoma (Cell Line: VCAP) [4]
MK-5108 + SCH-900776 DCUFS33 SCH-900776 Adenocarcinoma (Cell Line: CAOV3) [4]
MK-5108 + SCH-900776 DCBWXWD SCH-900776 Adenocarcinoma (Cell Line: OVCAR3) [4]
MK-5108 + SCH-900776 DCGAT18 SCH-900776 Adenocarcinoma (Cell Line: A427) [4]
MK-5108 + SCH-900776 DC8TA85 SCH-900776 Adenocarcinoma (Cell Line: NCIH23) [4]
MK-5108 + SCH-900776 DC7Q4W3 SCH-900776 Adenocarcinoma (Cell Line: HCT116) [4]
MK-5108 + SCH-900776 DCUJWM8 SCH-900776 Germ cell tumour (Cell Line: PA1) [4]
MK-5108 + SCH-900776 DCDW1MY SCH-900776 Malignant melanoma (Cell Line: A375) [4]
MK-5108 + SCH-900776 DCSRLNB SCH-900776 Malignant melanoma (Cell Line: RPMI7951) [4]
MK-5108 + SCH-900776 DCPZPWL SCH-900776 Malignant melanoma (Cell Line: SKMEL30) [4]
MK-5108 + SCH-900776 DCHU1F9 SCH-900776 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-5108 + 10-hydroxycamptothecin DCVHLJC 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH23) [4]
MK-5108 + 10-hydroxycamptothecin DCDSOC2 10-hydroxycamptothecin Adenocarcinoma (Cell Line: COLO320DM) [4]
MK-5108 + 10-hydroxycamptothecin DCJE7HQ 10-hydroxycamptothecin Adenocarcinoma (Cell Line: DLD1) [4]
MK-5108 + 10-hydroxycamptothecin DCTU3AB 10-hydroxycamptothecin Germ cell tumour (Cell Line: PA1) [4]
MK-5108 + 10-hydroxycamptothecin DCNWGYJ 10-hydroxycamptothecin Malignant melanoma (Cell Line: RPMI7951) [4]
MK-5108 + 10-hydroxycamptothecin DC87YTV 10-hydroxycamptothecin Mesothelioma (Cell Line: MSTO) [4]
MK-5108 + 10-hydroxycamptothecin DCHH7K5 10-hydroxycamptothecin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-5108 + 10-hydroxycamptothecin DC24S20 10-hydroxycamptothecin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
MK-5108 + 10-hydroxycamptothecin DCT62Z8 10-hydroxycamptothecin Prostate carcinoma (Cell Line: VCAP) [4]
MK-5108 + SNX-2112 DCN2TZ2 SNX-2112 Adenocarcinoma (Cell Line: OVCAR3) [4]
MK-5108 + SNX-2112 DC10PCM SNX-2112 Adenocarcinoma (Cell Line: A427) [4]
MK-5108 + SNX-2112 DCBQ63R SNX-2112 Adenocarcinoma (Cell Line: DLD1) [4]
MK-5108 + SNX-2112 DCFPC6I SNX-2112 Adenocarcinoma (Cell Line: SW-620) [4]
MK-5108 + SNX-2112 DC7OKSR SNX-2112 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
MK-5108 + SNX-2112 DCTG90W SNX-2112 Malignant melanoma (Cell Line: SKMEL30) [4]
MK-5108 + SNX-2112 DCA3NDS SNX-2112 Malignant melanoma (Cell Line: UACC62) [4]
MK-5108 + SNX-2112 DCEITKI SNX-2112 Non small cell carcinoma (Cell Line: SKMES1) [4]
MK-5108 + SNX-2112 DCXBU3F SNX-2112 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-5108 + Erlotinib DCM4Q20 Erlotinib Adenocarcinoma (Cell Line: OVCAR3) [4]
MK-5108 + Erlotinib DC1ZH7A Erlotinib Adenocarcinoma (Cell Line: CAOV3) [4]
MK-5108 + Erlotinib DCLHP24 Erlotinib Adenocarcinoma (Cell Line: A427) [4]
MK-5108 + Erlotinib DCG37J1 Erlotinib Adenocarcinoma (Cell Line: NCIH1650) [4]
MK-5108 + Erlotinib DCPXROO Erlotinib Adenocarcinoma (Cell Line: NCIH2122) [4]
MK-5108 + Erlotinib DC76B4I Erlotinib Adenocarcinoma (Cell Line: NCIH23) [4]
MK-5108 + Erlotinib DC5TJ1Q Erlotinib Adenocarcinoma (Cell Line: NCIH520) [4]
MK-5108 + Erlotinib DCYSN5X Erlotinib Adenocarcinoma (Cell Line: COLO320DM) [4]
MK-5108 + Erlotinib DCK4QKP Erlotinib Adenocarcinoma (Cell Line: DLD1) [4]
MK-5108 + Erlotinib DCS3U2A Erlotinib Adenocarcinoma (Cell Line: HT29) [4]
MK-5108 + Erlotinib DCKVT7V Erlotinib Adenocarcinoma (Cell Line: SW-620) [4]
MK-5108 + Erlotinib DCXAF9D Erlotinib Adenocarcinoma (Cell Line: HCT116) [4]
MK-5108 + Erlotinib DCIO91C Erlotinib Amelanotic melanoma (Cell Line: A2058) [4]
MK-5108 + Erlotinib DCBZQZR Erlotinib Germ cell tumour (Cell Line: PA1) [4]
MK-5108 + Erlotinib DC1OL2T Erlotinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
MK-5108 + Erlotinib DCX2EF7 Erlotinib Malignant melanoma (Cell Line: HT144) [4]
MK-5108 + Erlotinib DCKGI43 Erlotinib Malignant melanoma (Cell Line: RPMI7951) [4]
MK-5108 + Erlotinib DCQV03K Erlotinib Malignant melanoma (Cell Line: SKMEL30) [4]
MK-5108 + Erlotinib DCVANOK Erlotinib Malignant melanoma (Cell Line: UACC62) [4]
MK-5108 + Erlotinib DC4KM6B Erlotinib Malignant melanoma (Cell Line: A375) [4]
MK-5108 + Erlotinib DCR914L Erlotinib Mesothelioma (Cell Line: MSTO) [4]
MK-5108 + Erlotinib DC51XGC Erlotinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-5108 + Erlotinib DCA4D1Y Erlotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
MK-5108 + Erlotinib DC0PT5I Erlotinib Prostate carcinoma (Cell Line: LNCAP) [4]
MK-5108 + Erlotinib DCEATRI Erlotinib Prostate carcinoma (Cell Line: VCAP) [4]
MK-5108 + Zoledronate DCUBBX3 Zoledronate Embryonal rhabdomyosarcoma (Cell Line: Rh36) [4]
MK-5108 + Zoledronate DCVHUDQ Zoledronate Hodgkin lymphoma (Cell Line: U-HO1) [4]
MK-5108 + MK-4827 DC5W0QB MK-4827 Adenocarcinoma (Cell Line: CAOV3) [4]
MK-5108 + MK-4827 DCPONMC MK-4827 Adenocarcinoma (Cell Line: OVCAR3) [4]
MK-5108 + MK-4827 DCR8G24 MK-4827 Adenocarcinoma (Cell Line: A427) [4]
MK-5108 + MK-4827 DCO2W8T MK-4827 Adenocarcinoma (Cell Line: NCIH2122) [4]
MK-5108 + MK-4827 DCNYE0W MK-4827 Adenocarcinoma (Cell Line: NCIH520) [4]
MK-5108 + MK-4827 DCOTPP6 MK-4827 Adenocarcinoma (Cell Line: COLO320DM) [4]
MK-5108 + MK-4827 DCGZ7WH MK-4827 Adenocarcinoma (Cell Line: DLD1) [4]
MK-5108 + MK-4827 DCE21DR MK-4827 Adenocarcinoma (Cell Line: HCT116) [4]
MK-5108 + MK-4827 DCT21UE MK-4827 Adenocarcinoma (Cell Line: HT29) [4]
MK-5108 + MK-4827 DCC3F5K MK-4827 Adenocarcinoma (Cell Line: SW-620) [4]
MK-5108 + MK-4827 DC0XA7R MK-4827 Amelanotic melanoma (Cell Line: A2058) [4]
MK-5108 + MK-4827 DCQO4VA MK-4827 Malignant melanoma (Cell Line: A375) [4]
MK-5108 + MK-4827 DC2QYN9 MK-4827 Malignant melanoma (Cell Line: RPMI7951) [4]
MK-5108 + MK-4827 DCND5UR MK-4827 Malignant melanoma (Cell Line: SKMEL30) [4]
MK-5108 + MK-4827 DCXDZ90 MK-4827 Mesothelioma (Cell Line: MSTO) [4]
MK-5108 + MK-4827 DCTRTM1 MK-4827 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-5108 + MK-4827 DCKW65Q MK-4827 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
MK-5108 + MK-4827 DCFEYQ1 MK-4827 Prostate carcinoma (Cell Line: VCAP) [4]
MK-5108 + Lomustine DCTQGNK Lomustine Adenocarcinoma (Cell Line: CAOV3) [4]
MK-5108 + Lomustine DCLL8FP Lomustine Adenocarcinoma (Cell Line: OVCAR3) [4]
MK-5108 + Lomustine DCFA2UY Lomustine Adenocarcinoma (Cell Line: NCIH23) [4]
MK-5108 + Lomustine DCYIDWC Lomustine Adenocarcinoma (Cell Line: COLO320DM) [4]
MK-5108 + Lomustine DCPJLJD Lomustine Adenocarcinoma (Cell Line: HCT116) [4]
MK-5108 + Lomustine DC2FWLJ Lomustine Adenocarcinoma (Cell Line: HT29) [4]
MK-5108 + Lomustine DCTSM72 Lomustine Adenocarcinoma (Cell Line: SW-620) [4]
MK-5108 + Lomustine DCE5G6U Lomustine Germ cell tumour (Cell Line: PA1) [4]
MK-5108 + Lomustine DC71E68 Lomustine Malignant melanoma (Cell Line: RPMI7951) [4]
MK-5108 + Lomustine DCXOI1H Lomustine Malignant melanoma (Cell Line: SKMEL30) [4]
MK-5108 + Lomustine DCLNHEK Lomustine Mesothelioma (Cell Line: MSTO) [4]
MK-5108 + Lomustine DC1F6QV Lomustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-5108 + Lomustine DCGF0MN Lomustine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
MK-5108 + Lomustine DCT3SNE Lomustine Prostate carcinoma (Cell Line: LNCAP) [4]
MK-5108 + Bortezomib DCOWOUY Bortezomib Adenocarcinoma (Cell Line: CAOV3) [4]
MK-5108 + Bortezomib DCJEJ1U Bortezomib Malignant melanoma (Cell Line: RPMI7951) [4]
MK-5108 + Bortezomib DCVRUK2 Bortezomib Mesothelioma (Cell Line: MSTO) [4]
MK-5108 + Bortezomib DCB43QW Bortezomib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-5108 + GSK525762 DCV1ATR GSK525762 Adenocarcinoma (Cell Line: OVCAR3) [4]
MK-5108 + GSK525762 DC1SWCL GSK525762 Adenocarcinoma (Cell Line: NCIH2122) [4]
MK-5108 + GSK525762 DCC5GD9 GSK525762 Adenocarcinoma (Cell Line: DLD1) [4]
MK-5108 + GSK525762 DCCTUH5 GSK525762 Malignant melanoma (Cell Line: A375) [4]
MK-5108 + GSK525762 DCLFO5V GSK525762 Malignant melanoma (Cell Line: HT144) [4]
MK-5108 + GSK525762 DCP097C GSK525762 Malignant melanoma (Cell Line: SKMEL30) [4]
MK-5108 + GSK525762 DCNP5R7 GSK525762 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-5108 + GSK525762 DC9X6TN GSK525762 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
MK-5108 + Sorafenib DC9HKGO Sorafenib Adenocarcinoma (Cell Line: OVCAR3) [4]
MK-5108 + Sorafenib DCXCWT9 Sorafenib Adenocarcinoma (Cell Line: A427) [4]
MK-5108 + Sorafenib DC0AT1A Sorafenib Adenocarcinoma (Cell Line: NCIH1650) [4]
MK-5108 + Sorafenib DCNQV13 Sorafenib Adenocarcinoma (Cell Line: NCIH23) [4]
MK-5108 + Sorafenib DCPWBBG Sorafenib Adenocarcinoma (Cell Line: NCIH520) [4]
MK-5108 + Sorafenib DCHV1WL Sorafenib Adenocarcinoma (Cell Line: COLO320DM) [4]
MK-5108 + Sorafenib DC5QSRV Sorafenib Adenocarcinoma (Cell Line: DLD1) [4]
MK-5108 + Sorafenib DC4SULA Sorafenib Adenocarcinoma (Cell Line: HCT116) [4]
MK-5108 + Sorafenib DCTBZF1 Sorafenib Adenocarcinoma (Cell Line: HT29) [4]
MK-5108 + Sorafenib DCLFUQ3 Sorafenib Adenocarcinoma (Cell Line: SW-620) [4]
MK-5108 + Sorafenib DC6FPGQ Sorafenib Germ cell tumour (Cell Line: PA1) [4]
MK-5108 + Sorafenib DC1FNH0 Sorafenib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
MK-5108 + Sorafenib DCQBBFT Sorafenib Malignant melanoma (Cell Line: A375) [4]
MK-5108 + Sorafenib DCAZK7P Sorafenib Malignant melanoma (Cell Line: HT144) [4]
MK-5108 + Sorafenib DCDP2PY Sorafenib Malignant melanoma (Cell Line: SKMEL30) [4]
MK-5108 + Sorafenib DCPONNG Sorafenib Malignant melanoma (Cell Line: UACC62) [4]
MK-5108 + Sorafenib DCE6I9H Sorafenib Mesothelioma (Cell Line: MSTO) [4]
MK-5108 + Sorafenib DCFC19C Sorafenib Non small cell carcinoma (Cell Line: SKMES1) [4]
MK-5108 + Sorafenib DCVMSP3 Sorafenib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-5108 + Sorafenib DCIWCUY Sorafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
MK-5108 + Sorafenib DCUITK2 Sorafenib Prostate carcinoma (Cell Line: VCAP) [4]
MK-5108 + MK-2206 DCY265F MK-2206 Adenocarcinoma (Cell Line: CAOV3) [4]
MK-5108 + MK-2206 DCWHZAE MK-2206 Adenocarcinoma (Cell Line: NCIH2122) [4]
MK-5108 + MK-2206 DCY1299 MK-2206 Adenocarcinoma (Cell Line: COLO320DM) [4]
MK-5108 + MK-2206 DCFKX03 MK-2206 Adenocarcinoma (Cell Line: HCT116) [4]
MK-5108 + MK-2206 DC2SRZJ MK-2206 Adenocarcinoma (Cell Line: HT29) [4]
MK-5108 + MK-2206 DCK1BZ6 MK-2206 Amelanotic melanoma (Cell Line: A2058) [4]
MK-5108 + MK-2206 DCLRBK8 MK-2206 Germ cell tumour (Cell Line: PA1) [4]
MK-5108 + MK-2206 DCAS0BF MK-2206 Malignant melanoma (Cell Line: A375) [4]
MK-5108 + MK-2206 DCA845T MK-2206 Malignant melanoma (Cell Line: UACC62) [4]
MK-5108 + MK-2206 DCODM2O MK-2206 Mesothelioma (Cell Line: MSTO) [4]
MK-5108 + MK-2206 DCYA4FR MK-2206 Non small cell carcinoma (Cell Line: SKMES1) [4]
MK-5108 + MK-2206 DCY0TYT MK-2206 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-5108 + MK-2206 DCI7MAO MK-2206 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
MK-5108 + MK-2206 DCABKON MK-2206 Prostate carcinoma (Cell Line: VCAP) [4]
MK-5108 + Vorinostat DCUXG7L Vorinostat Adenocarcinoma (Cell Line: CAOV3) [4]
MK-5108 + Vorinostat DCLQF33 Vorinostat Adenocarcinoma (Cell Line: DLD1) [4]
MK-5108 + Vorinostat DCREZHD Vorinostat Adenocarcinoma (Cell Line: SW-620) [4]
MK-5108 + Vorinostat DCFX8YB Vorinostat Amelanotic melanoma (Cell Line: A2058) [4]
MK-5108 + Vorinostat DCJGOYE Vorinostat Germ cell tumour (Cell Line: PA1) [4]
MK-5108 + Vorinostat DCG7Z2J Vorinostat Large cell lung carcinoma (Cell Line: NCI-H460) [4]
MK-5108 + Vorinostat DC2OSVM Vorinostat Malignant melanoma (Cell Line: RPMI7951) [4]
MK-5108 + Vorinostat DCVZT9N Vorinostat Malignant melanoma (Cell Line: SKMEL30) [4]
MK-5108 + Vorinostat DCN0807 Vorinostat Malignant melanoma (Cell Line: UACC62) [4]
MK-5108 + Vorinostat DCONO8P Vorinostat Mesothelioma (Cell Line: MSTO) [4]
MK-5108 + Vorinostat DC48P5X Vorinostat Non small cell carcinoma (Cell Line: SKMES1) [4]
MK-5108 + Vorinostat DCSXGZM Vorinostat Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-5108 + Vorinostat DCNQT6C Vorinostat Prostate carcinoma (Cell Line: VCAP) [4]
MK-5108 + Dasatinib DCJHT1N Dasatinib Adenocarcinoma (Cell Line: CAOV3) [4]
MK-5108 + Dasatinib DCDAUVE Dasatinib Adenocarcinoma (Cell Line: A427) [4]
MK-5108 + Dasatinib DCHTDLJ Dasatinib Adenocarcinoma (Cell Line: NCIH520) [4]
MK-5108 + Dasatinib DCTVEUS Dasatinib Adenocarcinoma (Cell Line: DLD1) [4]
MK-5108 + Dasatinib DCCS3KO Dasatinib Adenocarcinoma (Cell Line: HT29) [4]
MK-5108 + Dasatinib DCEBA58 Dasatinib Adenocarcinoma (Cell Line: SW-620) [4]
MK-5108 + Dasatinib DCRYI17 Dasatinib Amelanotic melanoma (Cell Line: A2058) [4]
MK-5108 + Dasatinib DCYYQPZ Dasatinib Germ cell tumour (Cell Line: PA1) [4]
MK-5108 + Dasatinib DCI223R Dasatinib Malignant melanoma (Cell Line: A375) [4]
MK-5108 + Dasatinib DCBTCOQ Dasatinib Malignant melanoma (Cell Line: UACC62) [4]
MK-5108 + Dasatinib DC9DXN6 Dasatinib Mesothelioma (Cell Line: MSTO) [4]
MK-5108 + Dasatinib DCVGLKA Dasatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
PD-0325901 + MK-5108 DCP1163 PD-0325901 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
PD-0325901 + MK-5108 DCL0UVU PD-0325901 Breast carcinoma (Cell Line: KPL1) [3]
PD-0325901 + MK-5108 DCZ63ZD PD-0325901 Breast carcinoma (Cell Line: OCUBM) [3]
PD-0325901 + MK-5108 DC9H9ZR PD-0325901 Carcinoma (Cell Line: EFM192B) [3]
PD-0325901 + MK-5108 DC13JAN PD-0325901 Carcinoma (Cell Line: MDAMB436) [3]
PD-0325901 + MK-5108 DCPK3XK PD-0325901 Invasive ductal carcinoma (Cell Line: T-47D) [3]
PD-0325901 + MK-5108 DC4VG20 PD-0325901 Adenocarcinoma (Cell Line: CAOV3) [4]
PD-0325901 + MK-5108 DCLIQTL PD-0325901 Adenocarcinoma (Cell Line: A427) [4]
PD-0325901 + MK-5108 DC2BD8G PD-0325901 Adenocarcinoma (Cell Line: NCIH520) [4]
PD-0325901 + MK-5108 DC6X43X PD-0325901 Adenocarcinoma (Cell Line: COLO320DM) [4]
PD-0325901 + MK-5108 DCLPDB2 PD-0325901 Adenocarcinoma (Cell Line: DLD1) [4]
PD-0325901 + MK-5108 DCX21OX PD-0325901 Germ cell tumour (Cell Line: PA1) [4]
PD-0325901 + MK-5108 DCRABSY PD-0325901 Malignant melanoma (Cell Line: HT144) [4]
PD-0325901 + MK-5108 DCMELQV PD-0325901 Malignant melanoma (Cell Line: RPMI7951) [4]
PD-0325901 + MK-5108 DC6KJQX PD-0325901 Malignant melanoma (Cell Line: UACC62) [4]
PD-0325901 + MK-5108 DCQ8YCC PD-0325901 Mesothelioma (Cell Line: MSTO) [4]
PD-0325901 + MK-5108 DCHTKG1 PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
PD-0325901 + MK-5108 DCE0KO9 PD-0325901 Prostate carcinoma (Cell Line: LNCAP) [4]
PMID28460551-Compound-2 + MK-5108 DCVI3GX PMID28460551-Compound-2 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
PMID28460551-Compound-2 + MK-5108 DCJ6PVD PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
PMID28460551-Compound-2 + MK-5108 DCLU1ME PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
PMID28460551-Compound-2 + MK-5108 DC66SN3 PMID28460551-Compound-2 Breast carcinoma (Cell Line: OCUBM) [3]
PMID28460551-Compound-2 + MK-5108 DCB3J1H PMID28460551-Compound-2 Carcinoma (Cell Line: EFM192B) [3]
PMID28460551-Compound-2 + MK-5108 DCFYG5U PMID28460551-Compound-2 Carcinoma (Cell Line: MDAMB436) [3]
PMID28460551-Compound-2 + MK-5108 DCZ4S79 PMID28460551-Compound-2 Colon carcinoma (Cell Line: RKO) [3]
PMID28460551-Compound-2 + MK-5108 DCFZST1 PMID28460551-Compound-2 Invasive ductal carcinoma (Cell Line: T-47D) [3]
PMID28460551-Compound-2 + MK-5108 DCBM0RO PMID28460551-Compound-2 Adenocarcinoma (Cell Line: CAOV3) [4]
PMID28460551-Compound-2 + MK-5108 DCY6SDD PMID28460551-Compound-2 Adenocarcinoma (Cell Line: OVCAR3) [4]
PMID28460551-Compound-2 + MK-5108 DCTOOD7 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH1650) [4]
PMID28460551-Compound-2 + MK-5108 DC8TY1R PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH2122) [4]
PMID28460551-Compound-2 + MK-5108 DC6SRZY PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH520) [4]
PMID28460551-Compound-2 + MK-5108 DCOQNFA PMID28460551-Compound-2 Adenocarcinoma (Cell Line: COLO320DM) [4]
PMID28460551-Compound-2 + MK-5108 DCGSBFD PMID28460551-Compound-2 Adenocarcinoma (Cell Line: DLD1) [4]
PMID28460551-Compound-2 + MK-5108 DCV3WK5 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: SW-620) [4]
PMID28460551-Compound-2 + MK-5108 DCLEVTS PMID28460551-Compound-2 Malignant melanoma (Cell Line: A375) [4]
PMID28460551-Compound-2 + MK-5108 DCZ1AZF PMID28460551-Compound-2 Malignant melanoma (Cell Line: RPMI7951) [4]
PMID28460551-Compound-2 + MK-5108 DCINR6T PMID28460551-Compound-2 Malignant melanoma (Cell Line: SKMEL30) [4]
PMID28460551-Compound-2 + MK-5108 DCB70AW PMID28460551-Compound-2 Malignant melanoma (Cell Line: UACC62) [4]
PMID28460551-Compound-2 + MK-5108 DCMDD82 PMID28460551-Compound-2 Mesothelioma (Cell Line: MSTO) [4]
PMID28460551-Compound-2 + MK-5108 DCD52I9 PMID28460551-Compound-2 Non small cell carcinoma (Cell Line: SKMES1) [4]
PMID28460551-Compound-2 + MK-5108 DCWAX3M PMID28460551-Compound-2 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
PMID28460551-Compound-2 + MK-5108 DCKA1TH PMID28460551-Compound-2 Prostate carcinoma (Cell Line: VCAP) [4]
SCH 727965 + MK-5108 DCHYKG3 SCH 727965 Adenocarcinoma (Cell Line: HCT116) [2]
SCH 727965 + MK-5108 DCCWBWD SCH 727965 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
SCH 727965 + MK-5108 DC1J31K SCH 727965 Invasive ductal carcinoma (Cell Line: T-47D) [3]
SCH 727965 + MK-5108 DCPA2ZY SCH 727965 Adenocarcinoma (Cell Line: CAOV3) [4]
SCH 727965 + MK-5108 DCUW6N3 SCH 727965 Adenocarcinoma (Cell Line: A427) [4]
SCH 727965 + MK-5108 DCADS4G SCH 727965 Adenocarcinoma (Cell Line: NCIH520) [4]
SCH 727965 + MK-5108 DCZBWR7 SCH 727965 Adenocarcinoma (Cell Line: COLO320DM) [4]
SCH 727965 + MK-5108 DCUODBQ SCH 727965 Adenocarcinoma (Cell Line: DLD1) [4]
SCH 727965 + MK-5108 DCCAV6I SCH 727965 Adenocarcinoma (Cell Line: HT29) [4]
SCH 727965 + MK-5108 DCCSGCB SCH 727965 Adenocarcinoma (Cell Line: SW-620) [4]
SCH 727965 + MK-5108 DCU98CA SCH 727965 Germ cell tumour (Cell Line: PA1) [4]
SCH 727965 + MK-5108 DCNSBDH SCH 727965 Malignant melanoma (Cell Line: A375) [4]
SCH 727965 + MK-5108 DCN7XPG SCH 727965 Malignant melanoma (Cell Line: RPMI7951) [4]
SCH 727965 + MK-5108 DCYT7CV SCH 727965 Malignant melanoma (Cell Line: SKMEL30) [4]
SCH 727965 + MK-5108 DCH18AH SCH 727965 Malignant melanoma (Cell Line: UACC62) [4]
SCH 727965 + MK-5108 DCVW1WR SCH 727965 Mesothelioma (Cell Line: MSTO) [4]
SCH 727965 + MK-5108 DC6TFTC SCH 727965 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
SCH 727965 + MK-5108 DC6VI1Z SCH 727965 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Taxol + MK-5108 DCBWEPY Taxol Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
Taxol + MK-5108 DCY402E Taxol Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Taxol + MK-5108 DC7Z562 Taxol Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Taxol + MK-5108 DCU9KRX Taxol Breast carcinoma (Cell Line: OCUBM) [3]
Taxol + MK-5108 DCNS58T Taxol Carcinoma (Cell Line: EFM192B) [3]
Taxol + MK-5108 DCLFAOP Taxol Carcinoma (Cell Line: MDAMB436) [3]
Taxol + MK-5108 DCNN52G Taxol Colon adenocarcinoma (Cell Line: LOVO) [3]
Taxol + MK-5108 DCEJTCT Taxol Invasive ductal carcinoma (Cell Line: T-47D) [3]
Taxol + MK-5108 DC6EEQ1 Taxol Adenocarcinoma (Cell Line: CAOV3) [4]
Taxol + MK-5108 DC0U3B1 Taxol Adenocarcinoma (Cell Line: A427) [4]
Taxol + MK-5108 DCWJK29 Taxol Adenocarcinoma (Cell Line: NCIH1650) [4]
Taxol + MK-5108 DC8X8MF Taxol Adenocarcinoma (Cell Line: NCIH2122) [4]
Taxol + MK-5108 DCAY37I Taxol Adenocarcinoma (Cell Line: NCIH23) [4]
Taxol + MK-5108 DCLWNDA Taxol Adenocarcinoma (Cell Line: NCIH520) [4]
Taxol + MK-5108 DCXOZI7 Taxol Adenocarcinoma (Cell Line: COLO320DM) [4]
Taxol + MK-5108 DCCX2OC Taxol Adenocarcinoma (Cell Line: DLD1) [4]
Taxol + MK-5108 DCAZ0ZG Taxol Adenocarcinoma (Cell Line: SW-620) [4]
Taxol + MK-5108 DCF7PIV Taxol Amelanotic melanoma (Cell Line: A2058) [4]
Taxol + MK-5108 DC6AI7I Taxol Germ cell tumour (Cell Line: PA1) [4]
Taxol + MK-5108 DC6KJ76 Taxol Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Taxol + MK-5108 DCW9M6D Taxol Malignant melanoma (Cell Line: RPMI7951) [4]
Taxol + MK-5108 DCD8CR0 Taxol Malignant melanoma (Cell Line: SKMEL30) [4]
Taxol + MK-5108 DC59QWU Taxol Mesothelioma (Cell Line: MSTO) [4]
Taxol + MK-5108 DC4ZLGG Taxol Non small cell carcinoma (Cell Line: SKMES1) [4]
Taxol + MK-5108 DCU846O Taxol Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Taxol + MK-5108 DCG0S7C Taxol Prostate carcinoma (Cell Line: VCAP) [4]
Topotecan + MK-5108 DC0B4DZ Topotecan Breast carcinoma (Cell Line: OCUBM) [3]
Topotecan + MK-5108 DC0A5IB Topotecan Carcinoma (Cell Line: EFM192B) [3]
Topotecan + MK-5108 DCKXV7I Topotecan Colon adenocarcinoma (Cell Line: LOVO) [3]
Topotecan + MK-5108 DCENTX1 Topotecan Adenocarcinoma (Cell Line: OVCAR3) [4]
Topotecan + MK-5108 DCC8RSG Topotecan Adenocarcinoma (Cell Line: A427) [4]
Topotecan + MK-5108 DCN1HHM Topotecan Adenocarcinoma (Cell Line: NCIH2122) [4]
Topotecan + MK-5108 DCT4ZHB Topotecan Adenocarcinoma (Cell Line: NCIH520) [4]
Topotecan + MK-5108 DCCLYBR Topotecan Adenocarcinoma (Cell Line: COLO320DM) [4]
Topotecan + MK-5108 DC13C5B Topotecan Adenocarcinoma (Cell Line: DLD1) [4]
Topotecan + MK-5108 DCDAJE5 Topotecan Adenocarcinoma (Cell Line: HCT116) [4]
Topotecan + MK-5108 DC4F7K9 Topotecan Adenocarcinoma (Cell Line: HT29) [4]
Topotecan + MK-5108 DCVI8L7 Topotecan Adenocarcinoma (Cell Line: SW-620) [4]
Topotecan + MK-5108 DC7MB92 Topotecan Amelanotic melanoma (Cell Line: A2058) [4]
Topotecan + MK-5108 DCQTLT8 Topotecan Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Topotecan + MK-5108 DCX08VO Topotecan Germ cell tumour (Cell Line: PA1) [4]
Topotecan + MK-5108 DC7UDJZ Topotecan Malignant melanoma (Cell Line: A375) [4]
Topotecan + MK-5108 DCW552U Topotecan Malignant melanoma (Cell Line: SKMEL30) [4]
Topotecan + MK-5108 DCEO6HT Topotecan Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Topotecan + MK-5108 DCRVT2C Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Vinblastine + MK-5108 DC032GV Vinblastine Adenocarcinoma (Cell Line: CAOV3) [2]
Vinblastine + MK-5108 DCIO4D9 Vinblastine Adenocarcinoma (Cell Line: NCIH2122) [2]
Vinblastine + MK-5108 DCF2ND9 Vinblastine Adenocarcinoma (Cell Line: NCIH23) [2]
Vinblastine + MK-5108 DCBY7IT Vinblastine Adenocarcinoma (Cell Line: COLO320DM) [2]
Vinblastine + MK-5108 DCY4ST9 Vinblastine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
Vinblastine + MK-5108 DC2PVUP Vinblastine Malignant melanoma (Cell Line: HT144) [2]
Vinblastine + MK-5108 DCFO37Z Vinblastine Malignant melanoma (Cell Line: RPMI7951) [2]
Vinblastine + MK-5108 DCFA0MZ Vinblastine Malignant melanoma (Cell Line: SKMEL30) [2]
Vinblastine + MK-5108 DC9ZQEP Vinblastine Malignant melanoma (Cell Line: UACC62) [2]
Vinblastine + MK-5108 DCF6HJP Vinblastine Mesothelioma (Cell Line: MSTO) [2]
Vinblastine + MK-5108 DCXOLX5 Vinblastine Non small cell carcinoma (Cell Line: SKMES1) [2]
Vinblastine + MK-5108 DC2Z0KZ Vinblastine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
Vinblastine + MK-5108 DCZHIW1 Vinblastine Prostate carcinoma (Cell Line: LNCAP) [2]
Vinblastine + MK-5108 DC2USGX Vinblastine Prostate carcinoma (Cell Line: VCAP) [2]
Vinblastine + MK-5108 DCZKNMT Vinblastine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Vinblastine + MK-5108 DCG7CLQ Vinblastine Breast carcinoma (Cell Line: OCUBM) [3]
Vinblastine + MK-5108 DCHGFXN Vinblastine Carcinoma (Cell Line: MDAMB436) [3]
Vinblastine + MK-5108 DC12X2E Vinblastine Invasive ductal carcinoma (Cell Line: T-47D) [3]
Vinblastine + MK-5108 DCDEM1O Vinblastine Rectal adenocarcinoma (Cell Line: SW837) [3]
Vinorelbine + MK-5108 DCL3MZK Vinorelbine Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Vinorelbine + MK-5108 DC3U39P Vinorelbine Breast carcinoma (Cell Line: OCUBM) [3]
Vinorelbine + MK-5108 DCVVJGC Vinorelbine Carcinoma (Cell Line: EFM192B) [3]
Vinorelbine + MK-5108 DC5NZD6 Vinorelbine Carcinoma (Cell Line: MDAMB436) [3]
Vinorelbine + MK-5108 DCUSTTV Vinorelbine Colon adenocarcinoma (Cell Line: LOVO) [3]
Vinorelbine + MK-5108 DCHFE4M Vinorelbine Invasive ductal carcinoma (Cell Line: T-47D) [3]
Vinorelbine + MK-5108 DCKFSNI Vinorelbine Adenocarcinoma (Cell Line: CAOV3) [4]
Vinorelbine + MK-5108 DCH5AMG Vinorelbine Adenocarcinoma (Cell Line: OVCAR3) [4]
Vinorelbine + MK-5108 DCD2YW4 Vinorelbine Adenocarcinoma (Cell Line: NCIH1650) [4]
Vinorelbine + MK-5108 DCB5MGU Vinorelbine Adenocarcinoma (Cell Line: NCIH23) [4]
Vinorelbine + MK-5108 DCRZVHL Vinorelbine Adenocarcinoma (Cell Line: COLO320DM) [4]
Vinorelbine + MK-5108 DCPFTOH Vinorelbine Adenocarcinoma (Cell Line: HT29) [4]
Vinorelbine + MK-5108 DCY3XYC Vinorelbine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Vinorelbine + MK-5108 DCVAL52 Vinorelbine Germ cell tumour (Cell Line: PA1) [4]
Vinorelbine + MK-5108 DCRU0NP Vinorelbine Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vinorelbine + MK-5108 DC9S3I1 Vinorelbine Malignant melanoma (Cell Line: SKMEL30) [4]
Vinorelbine + MK-5108 DC27QDM Vinorelbine Mesothelioma (Cell Line: MSTO) [4]
Vinorelbine + MK-5108 DCL02YT Vinorelbine Prostate carcinoma (Cell Line: LNCAP) [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 568 DrugCom(s)

References

1 ClinicalTrials.gov (NCT00543387) Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001 AM4). U.S. National Institutes of Health.
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
4 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.